Leerink Partners analyst Mike Kratky has reiterated their bullish stance on VCEL stock, giving a Buy rating on April 14.
Mike Kratky has given his Buy rating due to a combination of factors that highlight Vericel’s strong market position and resilience against external economic pressures. The company has assured that the impact of current or future tariffs on its business operations in 2025 and 2026 will be minimal. This is largely because Vericel’s manufacturing is U.S.-based, with most materials sourced domestically, and they maintain a significant safety stock of essential materials.
Furthermore, the company’s growth prospects are promising, particularly with the increasing adoption of MACI and the anticipated contributions from MACI Arthro in the fiscal year 2025. These factors, combined with the company’s strategic positioning and operational efficiencies, support a positive outlook, making Vericel an attractive investment opportunity despite market volatility.
Kratky covers the Healthcare sector, focusing on stocks such as Dexcom, NeuroPace, and Edwards Lifesciences. According to TipRanks, Kratky has an average return of 10.4% and a 36.89% success rate on recommended stocks.
In another report released on April 14, BTIG also maintained a Buy rating on the stock with a $60.00 price target.